Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05197270 · ClinicalTrials.gov registry record · Phase 1

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

A Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
215
Enrollment target
20
Study locations

NCT05197270: Recruiting Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.

NCT05197270 is a Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 215 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05197270, a Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
215 participants
Enrollment target
20
Study locations

Study Summary

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.

Interventions

  • BIOLOGICAL 4D-150 IVT
  • BIOLOGICAL Aflibercept IVT

Study Locations (20)

Florida

  • Rand Eye Institute - Deerfield Beach
  • Retina Vitreous Consultants, LLP DBA Retina Group of Florida - Fort Lauderdale
  • Vitreo Retinal Associates - Gainesville
  • Florida Eye Associates - Melbourne
  • Retinal Specialty Institute - Pensacola
  • Retina Vitreous Associates of Florida - Tampa

California

  • California Retina Consultants - Oxnard
  • Retinal Consultants Medical Group - Sacramento

Arizona

  • Barnet Delaney Perkins Eye Center - Phoenix

Colorado

  • Colorado Retina Associates - Lakewood

Illinois

  • University Retina and Macula Associates - Oak Forest

Indiana

  • Retina Partners Midwest - Carmel

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

Massachusetts

  • Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center - Boston

Trial Details

FieldValue
Enrollment Target 215 participants
Start Date 2021-12-09
Est. Completion 2031-01
Phase Phase 1
4D Molecular Therapeutics

9 total trials

What NCT05197270 shows while recruiting

NCT05197270 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher).

The record links to 1 condition, with Neovascular (Wet) Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT is the first listed.

NCT05197270 names 20 study sites across 14 states, led by Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05197270 about?

NCT05197270 is a clinical study titled "4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration". Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.

What is the current status of trial NCT05197270?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2021-12-09. Estimated completion is 2031-01.

What conditions does trial NCT05197270 study?

This clinical trial studies the following conditions: Neovascular (Wet) Age-Related Macular Degeneration.

What interventions are being tested in trial NCT05197270?

The interventions under investigation include: 4D-150 IVT (BIOLOGICAL), Aflibercept IVT (BIOLOGICAL).

Who is sponsoring clinical trial NCT05197270?

This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05197270 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neovascular (Wet) Age-Related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05197270's enrollment target sits among peer trials

215 244th of 2000 higher than 1,757 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05134012 · 215 participants · Phase 3

    RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

  • NCT05169970 · 215 participants · Phase 2

    A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

  • NCT05230199 · 215 participants · NA

    Sensory Optimization of the Hospital Environment

  • NCT05473429 · 215 participants · NA

    Characterization of Nociception Phenotype in Individuals With Intellectual Disability

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05197270, the US trial registry maintained by the National Library of Medicine. NCT05197270 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.